Literature DB >> 19294401

Extensive papillary carcinoma of the thyroid gland treated by external beam radiotherapy, surgery and postoperative radioactive iodine therapy.

Anjum Naveed1, F Kanaan, N O Tjernstrom.   

Abstract

The treatment of choice for well-differentiated thyroid carcinoma is surgery, radioactive iodine ablation and thyroid stimulating hormone suppression [Richard in Cancer 82:375-388, 1988; James et al. in Endocrinol Metab Clin North Am 37(2):497-509]. We report a case with an extensive papillary carcinoma of thyroid gland treated by external beam radiotherapy as a cytoreductive therapy followed by total thyroidectomy. Postoperatively the patient was given radioactive iodine. The patient is free from tumor a year after the treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19294401     DOI: 10.1007/s00405-009-0948-1

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  5 in total

Review 1.  External beam radiation therapy for thyroid cancer.

Authors:  James D Brierley; Richard W Tsang
Journal:  Endocrinol Metab Clin North Am       Date:  2008-06       Impact factor: 4.741

2.  External radiotherapy and radionuclide in the treatment of thyroid cancer.

Authors:  M Tubiana
Journal:  World J Surg       Date:  1981-01       Impact factor: 3.352

3.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Authors:  R W Tsang; J D Brierley; W J Simpson; T Panzarella; M K Gospodarowicz; S B Sutcliffe
Journal:  Cancer       Date:  1998-01-15       Impact factor: 6.860

4.  Postoperative irradiation for thyroid cancer.

Authors:  P Phlips; C Hanzen; G Andry; P Van Houtte; J Früuling
Journal:  Eur J Surg Oncol       Date:  1993-10       Impact factor: 4.424

5.  External radiotherapy in thyroid cancers.

Authors:  M Tubiana; E Haddad; M Schlumberger; C Hill; P Rougier; D Sarrazin
Journal:  Cancer       Date:  1985-05-01       Impact factor: 6.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.